Genmab A/S

Ladies and gentlemen, thank you for standing by and welcome to GENMAD First Quarter Report 2020 Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you will need to press Start 1 on your telephone and wait for your name to be announced. During this telephone conference, you may be presented with forward-looking statements that include words such as believes, anticipates, plans or expects. Actual results might differ materially, for example, as a result of delays or unsuccessful development projects. GEMMA is not under an obligation to update statements regarding the future, nor to confirm such statements in relation to actual results unless this is required by law. Please also note then GEDMAP may hold your personal data as indicated by you as part of our investor relations outreach activities in order to update you on GEDMAP going forward. Please refer to our website for more information on GEDMAP and our privacy policy. I must advise you that this conference is being recorded today and now I would like to hand the conference over one of your speakers today, Jan van de Winkel. Please go ahead. Please go ahead. We have some technical difficulties, so please stand by. Please stand by when we dial out to our speaker today. Thank you. Thank you for waiting. Please go ahead. Thank you.

All right. Thank you. Hello and welcome to the GenMob conference call to discuss the company's financial results for the quarter ended March 31st 2020. Our CFO Anthony Pagano is joining me on today's call and you will also have a brief introduction to our new Chief Operating Officer Anthony Mancini. Before I discuss the progress that GenMob has already made this year, I would like to address the unique circumstances under which we are presenting our first quarter results. The COVID-19 pandemic continues to pose unprecedented challenges in our lives and to companies across the globe. At Genmob, we are closely monitoring the evolving landscape created by this global health crisis and its potential impact on our employees, business and key priorities. 2019 was Genmob's strongest year to date, both with regards to our pipeline and to our financials. This solid foundation continues to position us very well for the future and for future growth, despite the uncertainty due to COVID-19. Let's move to slide two. As already said, we will be making forward-looking statements, so please keep that in mind as we go through this call. Let's now move to slide three. Now let's turn to some of the highlights from the first quarter of 2020. First, I would like to remind you of the recent changes to our executive management team. Anthony Pagano took on his new role as CFO at the end of February, and you will be hearing from him later in today's presentation. At this point, I would like to introduce you to GenMob Chief Operating Officer Anthony Monsini, who joined us in March. In this newly created role, Anthony is responsible for ensuring that GenMob will be able to bring its innovative and differentiated medicines to patients around the world with its leadership of our commercial, corporate development, business development, and IT functions. I will now turn the presentation to Anthony Mancini to introduce himself. Anthony, please go ahead.

Thanks, Jan. Good afternoon and good evening, everyone. I'm excited to have joined GenMab and my first month here has been extremely positive. I'm very pleased to take on the commercial IT as well as the business and corporate development responsibility as we work together to achieve our vision of bringing our own differentiated medicines to the market. I've been impressed by the highly talented people, the innovative spirit, and the relentless drive at GenMab through the COVID-19 challenges and overall. Let me just share a little bit about my background. The vast majority of my career was spent at Bristol Myers Squibb where I had the opportunity to launch and lead large teams of over 1,100 people across various functions and therapeutic areas, including oncology, hematology, immunology, transplant, and cardiovascular disease. I've also had the privilege of leading several very successful partnership-based brands in the United States and around the world. I believe GenMab is in a unique position. It has a track record of creating highly innovative medicines, a rich and differentiated clinical pipeline, a solid financial position, and a fantastic team. I'm really looking forward to continuing to work with the entire GenMab organization and our partners to bring innovative new cancer medicines to patients. And I'm also looking forward to meeting everyone on this call in person. With that, let me pass the call back to Jan.